Microsatellite and Single Nucleotide Polymorphisms in the Insulin-Like Growth Factor 1 Promoter with Insulin Sensitivity and Insulin Secretion

Ruyao Wang, Dandan Xu, Rui Liu, Lijie Zhao, Liling Hu, Ping Wu

Corresponding Author: Rui Liu, e-mail: lr3596@163.com

Source of support: The study was financially supported by A Key Project of Tianjin Bureau of Public Health (No. 12KG104)

Background: To investigate associations of the CA microsatellite and rs35767, rs5742612, and rs2288377 polymorphisms and the single nucleotide polymorphism (SNP) haplotypes with and without the CA microsatellite in the IGF1 promoter with insulin sensitivity and secretion.

Material/Methods: The CA microsatellite and SNPs were genotyped in 389 type 2 diabetes mellitus (T2DM) patients. A 75 g oral glucose tolerance test (OGTT) was given to all the participants. Associations of the genotypes and haplotypes with insulin sensitivity, insulin secretion, glucose tolerance, and insulin-like growth factor 1 (IGF1) were analyzed by ANCOVA (general linear model) and multiple linear regression, after controlling for gender, age, and BMI.

Results: The CA microsatellite, rs35767 polymorphisms, and SNP haplotypes with or without CA showed no significant association with metabolic parameters. The C allele of rs5742612 was found to be associated with decreased insulin sensitivity (HOMA-S index, $\beta$=-0.131, $P=0.008$; fasting insulin level, $\beta=0.022, P=0.006$) and increased insulin secretion (HOMA-B index, $\beta=0.099, P=0.008$; insulin AUC, $\beta=0.112, P=0.012$). The linear regression model also indicated that the A allele of rs2288377 was associated with decreased insulin sensitivity (HOMA-S index, $\beta=-0.159, P=0.001$; fasting insulin, $\beta=0.143, P=0.001$) and increased insulin secretion (HOMA-B index, $\beta=0.114, P=0.017$; insulin AUC, $\beta=0.042, P=0.002$).

Conclusions: The CA microsatellite and rs35767 have no genotype-related difference in insulin sensitivity or secretion. The rs5742612 and rs2288377 polymorphisms are significantly associated with insulin biology, with the TT genotype exhibiting higher insulin sensitivity and lower insulin secretion compared with carriers of the C allele and A allele, respectively, mostly attributed to the direct functional roles of the two loci.

MeSH Keywords: Insulin Resistance • Insulin-Like Growth Factor 1 • Microsatellite Repeats • Polymorphism, Single Nucleotide

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/902956
Background

Type 2 diabetes mellitus (T2DM) is a complex condition of hyperglycemia caused by impaired insulin sensitivity and deficient β cell function [1]. Sets of susceptibility loci involved in the process of insulin sensitivity and/or secretion have been proposed [2]. A meta-analysis conducted by the genome-wide association studies identified two loci associated with fasting insulin and insulin resistance and 16 loci associated with fasting glucose and β cell function [3]. Meanwhile, the genome-wide association studies elucidated 60 T2DM- and glycemic trait-related loci [4]. Another more recent study of the association of genetic scores with a range of metabolic measures in up to 18,565 individuals also validated the role of genetic variants as instruments for insulin resistance and secretion [5].

Insulin-like growth factor 1 (IGF1) has been reported to play important roles in regulating glucose homeostasis and insulin sensitivity [6]. There is evidence that IGFI gene deletion is associated with reduced insulin sensitivity [7], and IGFI treatment results in positive effects on insulin sensitivity [8–10]. A CA repeat microsatellite located on the 979 bp upstream of IGFI is often reported to correlate with insulin sensitivity and/or risk of T2DM. However, there are controversial hypotheses and observations regarding such an association. Some studies suggested a positive association between the CA19 (with 19 CA repeats) allele, which is the most common one, and increased risk of T2DM [11], whereas other studies observed an opposite association [12], implying that the microsatellite may not be the sole regulatory unit in the promoter region. Moreover, a recent study of the short- and long-term metabolic response to recombinant human growth hormone (GH) in GH-deficient adults suggested that the impact showed obvious gene specificity and after 1 year of GH, a significant worsening of insulin sensitivity was recorded only in homozygous CA19 repeats subjects [13]. Besides, it has been shown that a functional single-nucleotide polymorphism (SNP), rs35767: T>C (NM 000618.3: c.-1410T>C), was also associated with glucose homeostasis and insulin sensitivity in which carriers of the GG genotype exhibited lower insulin sensitivity and IGF1 concentrations compared with subjects carrying the A allele [14]. In this way, both the microsatellite and SNPs may have functional roles in the regulation of insulin sensitivity and insulin secretion.

In a systematic survey of human variations in the cis-regulatory regions, IGFI was 1 of the 23 genes that show consistent allelic imbalance, implying that certain functional elements lie within IGFI regulatory region among individuals [15]. This was confirmed in another study. Chen et al. revealed that there was strong linkage disequilibrium (LD) between the CA microsatellite and SNPs in the promoter of the IGFI gene, which constituted specific haplotype patterns in the population [16].

Material and Methods

Study subjects

This study included 389 Tianjin native patients of the Han nationality with T2DM, treated in Tianjin Union Medical Center from November 2012 to June 2014. T2DM was defined according to the 1999 clinical practice recommendations by the American Diabetes Association. We excluded individuals with Cushing syndrome, hyperthyroidism, or hypothyroidism; pregnancy; or history of cardiovascular disease or cancer. A simplified questionnaire for sex, age, and family history of T2DM and anthropometrical measurements of body mass index (BMI) was administered by trained nurses to all the participants. Blood samples were collected in the early morning after hospitalization and 8 hours of fasting. Venous blood samples were collected using tubes with coagulant. Participants were then given a standard 75 g oral glucose tolerance test (OGTT) with 60- and 120-min blood samples drawn. Serum glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL cholesterol), and low-density lipoprotein cholesterol (LDL cholesterol) were measured by enzymatic methods using an automatic biochemical analyzer ARCHITECT CI16000 (Abbott, Abbott Park, Illinois, USA) and a reagent kit provided by Roche, Switzerland. Serum insulin and peptide C concentrations were determined by the electrochemiluminescence method (Cobas e411, Roche, Switzerland) and the matched reagents. Serum levels of IGF1 were measured by the electrochemiluminescence method using Immulite 2000 (Siemens, Germany), with reagents from Diagnostic Products Corp. Hemoglobin A1C (HbA1C) was measured by high performance liquid chromatography using Hb9210 (Premier, China) with the matched reagents.

tagSNPs selection

According to previous studies, the evolutionarily conserved region (ECR) was defined by >75% identity between human and three other species [17, 18]. Three polymorphisms, rs35767: T>C (NM 000618.3: c.-1410T>C), rs5742612: T>C (NM000618.3: c.-705T>C), and rs2288377: T>A (NM 000618.3: c.-603T>A),
were selected as tagSNPs, as they covered 100% variance in the ECR of the IGF1 promoter. The SNP information was obtained from the National Center for Biotechnology Information (NCBI) dbSNP. Common haplotype was defined as haplotype with a frequency of >5% in the population.

**DNA analysis**

Genomic DNA was extracted from blood leukocytes using the High Pure Polymerase Chain Reaction (PCR) Template Preparation Kit (Tiangen Biotech, Beijing, China), according to the protocol of the manufacturer. DNA samples were stored at −80°C until use.

The CA microsatellite of the IGF1 gene located at 979 bp upstream from the transcription start site was determined by PCR and fragment analysis using the ABI-3730XL DNA Sequencer (Applied Biosystems, Foster City, California, USA). PCR primers were 5’- AGAAAAACACTTGGCACAAC-3’ and 5’-GCAAAGACTCTGCCCCAGCTG-3’ (Invitrogen, Shanghai, China). The forward primer was 5’ labeled with a fluorescent dye (FAM). The PCR reaction was performed in a final volume of 50 µL containing 10 ng of DNA, 10× PCR buffer 5 µL, 50 mm MgCl₂, 1.6 µL, 2 mm dNTPs 4 µL, 5 µm each of the primers 2 µL, and 1.5 units of Platinum® Taq DNA polymerase (Invitrogen Trading, Shanghai, China). The amplified conditions were 95°C/5 min followed by 35 thermal cycles (95°C/30 s, 60°C/30 s, and 72°C/30 s) and a final extension at 72°C/5 min. The length of amplified fragments was determined by GeneScan 3.0 and GeneMapper analysis software (Applied Biosystems, Foster City, California, USA). The fragments ranged in size from 227 to 257 bp, depending on the number of CA repeats.

Genotyping for rs35767, rs5742612, and rs2288377 in the promoter region was done by PCR followed by gene sequencing (ABI-3730XL, Applied Biosystems, Foster City, California, USA). The sequencing results were compared with reference sequences in NCBI. The sequence of forward and reverse primers of the three SNPs was designed according to NCBI. Primers for rs35767 were 5’-TTGGGCACATAGTAGACCTC-3’ and 5’-CAAAAGCCCAGAGCAGACAT- 3’ (405 bp); primers for rs5742612 and rs2288377 were 5’-GGTTTACAGCTCGGCAATGC-3’ and 5’-TCTGCTGGGACATGAAGACAC- 3’ (359 bp).

**Calculations**

The area under the curve (AUC) for insulin and glucose was calculated by the trapezoidal method. The homeostasis model assessment-sensitivity (HOMA-S) index was calculated as \( \frac{20 \times \text{fasting insulin} \times \text{fasting glucose}}{\text{fasting insulin} \times \text{fasting glucose}} \). The homeostasis model assessment-beta (HOMA-B) index was calculated as \( \frac{20 \times \text{fasting insulin}}{\text{fasting glucose} - 3.5} \).

**Statistical analysis**

Categorical variables were analyzed using a \( \chi^2 \) test. For intergroup comparisons, continuous normal distribution variables were analyzed by analysis of covariance (ANCOVA), general linear model, after adjusting for gender, age, and BMI, and expressed as mean ± standard deviations. Continuous non-normal distribution variables were analyzed by the Kruskal-Wallis H test and expressed as median (25%, 75%) percentiles. The Hardy-Weinberg equilibriums among the genotypes were in Hardy-Weinberg equilibrium by the \( \chi^2 \) test (all \( P>0.001 \)). Associations between the CA microsatellite, SNPs, haplotypes of the ECR, and continuous traits were estimated by multiple linear regression analysis controlling for gender, age, and BMI, and expressed as β and SE per allele, with non-normal distribution variables log-transformed first. The analysis was conducted according to both an additive and a dominant genetic model. All statistical analyses were performed according to SPSS 19.0 software. A two-sided \( P<0.05 \) was considered as statistically significant.

**Ethics**

The protocol for this study was compatible with the local ethical guidelines. The study was approved by the Academic Committees in Tianjin Union Medical Center. Informed consent was obtained from all patients.

**Results**

The study included 389 patients with T2DM. Clinical characteristics according to the CA microsatellite, SNPs, and haplotypes of the ECR by ANCOVA and associations of the CA microsatellite, SNPs, haplotypes with continuous traits by multiple linear regression analysis are shown in Tables 1–6 separately.

**CA microsatellite**

We compared other genotypes with the CA19/CA19 homozygote as it is the most common one. The CA microsatellite genotype did not show any significant association with gender, family history of T2DM, anthropometric or metabolic parameters, or IGF1 levels. However, we observed a significant difference in age, total cholesterol, and LDL cholesterol among subjects with different CA microsatellites. The linear regression analysis found no significant contribution of the CA microsatellite to metabolic parameters, after adjusting for gender, age, and BMI (Table 1).
|                                | CA19/CA19 | CA19/Other | Other/Other | P            | P (non-CA19/19 vs. CA19/19) | β      | SE  | R² (%) | P  |
|--------------------------------|-----------|------------|-------------|--------------|-----------------------------|--------|-----|--------|-----|
| N(M/F)                         | 34/17     | 81/57      | 121/79      | 0.608        | 0.362                       |        |     |        |     |
| Age (years)                    | 62±8      | 65±10      | 65±9        | 0.073        | 0.006                       |        |     |        |     |
| Family history of T2DM (Y/N)   | 23/28     | 82/56      | 111/89      | 0.213        | 0.131                       |        |     |        |     |
| **Anthropometry**              |           |            |             |              |                             |        |     |        |     |
| Height (cm)                    | 166.86±8.21 | 166.93±8.11 | 166.81±8.04 | 0.351        | 0.997                       |        |     |        |     |
| BMI (kg/m²)                    | 24.60±2.89 | 25.53±3.21 | 25.13±3.77  | 0.166        | 0.185                       |        |     |        |     |
| Total cholesterol (mmol/l)     | 3.54±1.29 | 3.21±1.10  | 3.10±1.06   | 0.035        | 0.016                       |        |     |        |     |
| Triacylglycerol (mmol/l)       | 1.50 (0.96, 2.15) | 1.35 (0.94, 1.80) | 1.32 (0.85, 1.86) | 0.284        | 0.116                       |        |     |        |     |
| HDL-cholesterol (mmol/l)       | 0.78 (0.63, 0.98) | 0.73 (0.58, 0.92) | 0.73 (0.55, 0.91) | 0.456        | 0.236                       |        |     |        |     |
| LDL-cholesterol (mmol/l)       | 1.94 (1.68, 2.64) | 1.87 (1.51, 2.48) | 1.44 (1.42, 2.36) | 0.070        | 0.039                       |        |     |        |     |
| **Total cholesterol (mmol/l)** | 0.68 (0.44, 0.98) | 0.61 (0.43, 0.82) | 0.61 (0.39, 0.83) | 0.254        | 0.099                       |        |     |        |     |
| **OGTT**                       |           |            |             |              |                             |        |     |        |     |
| Fasting insulin (mU/L)         | 12.46 (8.87, 24.37) | 11.19 (6.92, 23.00) | 11.35 (7.21, 21.40) | 0.809        | 0.515                       |        |     |        |     |
| 60-min insulin (mU/L)          | 34.48 (18.10, 61.62) | 31.83 (17.96, 66.73) | 33.41 (19.44, 51.10) | 0.908        | 1.847                       |        |     |        |     |
| 120-min insulin (mU/L)         | 36.20 (20.02, 71.71) | 37.38 (20.78, 69.90) | 35.93 (22.37, 66.12) | 0.957        | 0.791                       |        |     |        |     |
| Fasting peptide C (ng/ml)      | 2.56 (1.74, 4.08) | 2.62 (2.03, 3.87) | 1.86 (3.77) | 0.447        | 0.776                       |        |     |        |     |
| 60-min peptide C (ng/ml)       | 2.70 (3.14, 8.20) | 3.29 (4.77, 7.13) | 4.71 (3.16, 6.69) | 0.893        | 0.920                       |        |     |        |     |
| 120-min peptide C (ng/ml)      | 5.91 (4.04, 9.21) | 6.07 (4.03, 9.28) | 6.03 (3.97, 8.71) | 0.916        | 0.783                       |        |     |        |     |
| Fasting glucose (mmol/L)       | 10.25±4.51 | 10.65±4.03 | 10.41±4.06  | 0.705        | 0.516                       |        |     |        |     |
| 60-min glucose (mmol/L)        | 16.69±3.99 | 16.72±4.01 | 16.88±4.15  | 0.901        | 0.771                       |        |     |        |     |
| 120-min glucose (mmol/L)       | 18.32±5.62 | 18.64±4.94 | 18.50±5.33  | 0.941        | 0.849                       |        |     |        |     |
| **Metastatic parameters**      |           |            |             |              |                             |        |     |        |     |
| **Insulin sensitivity**        |           |            |             |              |                             |        |     |        |     |
| HOMA-S index*                  | 0.22 (0.11, 0.33) | 0.20 (0.09, 0.36) | 0.20 (0.10, 0.36) | 0.951 | 0.807 | -0.010 | - | - | 0.836 |
| Fasting insulin (mU/L)*        | 12.46 (8.87, 24.37) | 11.19 (6.92, 23.00) | 11.35 (7.21, 21.40) | 0.809 | 0.515 | -0.002 | - | - | 0.963 |
Table 1 continued. Clinical characteristics of the 389 study population according to different CA microsatellite and multiple linear regression analysis for association of CA repeat with metastatic traits.

| CA19/CA19 | CA19/Other | Other/Other | P (non-CA19/CA19 vs. CA19/19) | β | SE | R² (%) | P |
|-----------|------------|-------------|--------------------------------|----|----|--------|----|
| Insulin secretion | | | | | | | |
| HOMA-B index (%) | 50.28 (25.39, 102.01) | 40.69 (20.70, 98.23) | 43.79 (23.21, 88.08) | 0.630 | 0.368 | −0.027 | − | − | 0.585 |
| Insulin AUC (mU/L/h) | 65.38 (33.62, 94.36) | 59.67 (33.18, 103.89) | 61.48 (35.32, 96.12) | 0.935 | 0.802 | 0.001 | − | − | 0.979 |

Glucose tolerance

| Glucose AUC (mmol/L h) | 30.98±8.17 | 31.37±7.64 | 31.36±7.99 | 0.929 | 0.702 | 0.010 | − | − | 0.836 |
| Fasting glucose (mmol/L) | 10.25±4.51 | 10.65±4.03 | 10.41±4.06 | 0.705 | 0.705 | 0.018 | − | − | 0.723 |
| 120-min glucose (mmol/L) | 18.32±5.62 | 18.64±4.94 | 18.50±5.33 | 0.941 | 0.941 | 0.010 | − | − | 0.842 |
| IGF1 (ng/ml) | 136.70±71.18 | 124.94±63.64 | 135.52±65.40 | 0.402 | 0.847 | 0.003 | − | − | 0.959 |
| HbA1c (%) | 7.84±1.78 | 8.13±1.79 | 8.08±1.82 | 0.675 | 0.396 | 0.043 | − | − | 0.392 |

T2DM – type 2 diabetes mellitus; IGF1 – insulin like growth factor 1; CA – cytosine-adenosine; BMI – body mass index; OGTT – oral glucose tolerance test; HDL-cholesterol – high-density lipoprotein cholesterol; LDL-cholesterol – low-density lipoprotein cholesterol; HbA1c – hemoglobin A1c; AUC – area under the curve; HOMA-S – homeostasis model assessment-sensitivity; HOMA-B – homeostasis model assessment-beta. * Log-transformed before multiple linear regression analysis.

Table 2. Clinical characteristics of the 389 study population according to SNP rs35767 and multiple linear regression analysis for association of rs35767 with metastatic traits.

| CC | CT | TT | P | P (CT+ TT vs. CC) | β | SE | R² (%) | P |
|----|----|----|---|-------------------|----|----|--------|----|
| N (M/F) | 92/61 | 109/70 | 35/22 | 0.983 | 0.195 |
| Age (years) | 65±9 | 65±9 | 67±10 | 0.370 | 0.838 |
| Family history of T2DM (Y/N) | 84/69 | 102/77 | 30/27 | 0.831 | 0.917 |

Anthropometry

| Height (cm) | 166.68±8.00 | 166.75±7.98 | 167.68±8.61 | 0.574 | 0.725 |
| Total cholesterol (mmol/l) | 3.40±1.21 | 3.07±1.04 | 3.01±1.01 | 0.015 | 0.004 |
| Triacylglycerol (mmol/l) | 1.42 (0.91, 2.02) | 1.30 (0.92, 1.80) | 1.25 (0.82, 1.94) | 0.257 | 0.115 |
| HDL-cholesterol (mmol/l) | 0.72 (0.58, 0.91) | 0.75 (0.58, 0.96) | 0.75 (0.60, 0.89) | 0.834 | 0.760 |
| LDL-cholesterol (mmol/l) | 2.03 (1.57, 2.63) | 1.82 (1.46, 2.34) | 1.93 (1.37, 2.30) | 0.028 | 0.008 |
| VLDL-cholesterol (mmol/l) | 0.65 (0.42, 0.92) | 0.59 (0.42, 0.82) | 0.55 (0.36, 0.81) | 0.141 | 0.095 |

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Table 2 continued. Clinical characteristics of the 389 study population according to SNP rs35767 and multiple linear regression analysis for association of rs35767 with metastatic traits.

|                | CC (n=131) | CT (n=131) | TT (n=225) | P (CT+TT vs. CC) | β | SE | R² (%) | P  |
|----------------|------------|------------|------------|------------------|---|----|--------|----|
| **OGTT**       |            |            |            |                  |   |    |        |    |
| Fasting insulin (mU/L) | 10.95 (6.49, 20.86) | 12.16 (7.63, 23.01) | 13.86 (8.27, 26.35) | 0.241 | 0.104 |
| 60-min insulin (mU/L)   | 30.50 (18.28, 53.58) | 33.48 (18.80, 59.72) | 34.93 (19.29, 51.16) | 0.533 | 0.262 |
| 120-min insulin (mU/L)  | 35.13 (19.70, 58.05) | 37.28 (22.61, 69.34) | 34.93 (21.91, 79.37) | 0.222 | 0.083 |
| **Fasting peptide C (ng/ml)** | 2.56 (1.78, 3.80) | 2.70 (2.02, 3.93) | 2.67 (1.73, 3.50) | 0.457 | 0.350 |
| 60-min peptide C (ng/ml) | 4.53 (3.21, 6.25) | 4.85 (3.14, 7.47) | 4.72 (3.31, 6.23) | 0.495 | 0.358 |
| 120-min peptide C (ng/ml) | 5.77 (4.02, 7.97) | 6.35 (4.03, 9.69) | 6.50 (3.75, 8.53) | 0.434 | 0.253 |
| **Fasting glucose (mmol/L)** | 10.47±4.34 | 10.69±4.18 | 9.80±3.04 | 0.372 | 0.973 |
| 60-min glucose (mmol/L)   | 16.72±4.19 | 16.87±3.86 | 16.80±4.45 | 0.915 | 0.983 |
| 120-min glucose (mmol/L)  | 18.51±5.39 | 18.38±5.25 | 19.04±4.72 | 0.802 | 0.847 |
| **Insulin sensitivity**  |            |            |            |                  |   |    |        |    |
| HOMA-S index*          | 0.22 (0.11, 0.42) | 0.20 (0.08, 0.33) | 0.18 (0.09, 0.26) | 0.195 | 0.100 | -0.080 | -- |
| Fasting insulin (mU/L)* | 10.95 (6.49, 20.86) | 12.16 (7.63, 23.01) | 13.86 (8.27, 26.35) | 0.241 | 0.104 | 0.087 | -- |
| **Insulin secretion**   |            |            |            |                  |   |    |        |    |
| HOMA-B index (%)*      | 42.65 (21.13, 89.05) | 46.37 (23.00, 96.67) | 42.99 (22.51, 102.61) | 0.544 | 0.327 | 0.071 | -- |
| Insulin AUC (mmol/L*h)  | 56.93 (31.40, 88.76) | 62.47 (37.95, 115.87) | 61.70 (35.39, 105.96) | 0.411 | 0.182 | 0.071 | -- |
| **Glucose tolerance**  |            |            |            |                  |   |    |        |    |
| Glucose AUC (mmol/L*h)  | 31.24±8.22 | 31.40±7.75 | 31.21±7.88 | 0.949 | 0.798 | 0.008 | -- |
| Fasting glucose (mmol/L) | 10.47±4.34 | 10.69±4.18 | 9.80±3.04 | 0.372 | 0.973 | -0.006 | -- |
| 120-min glucose (mmol/L) | 18.51±5.39 | 18.38±5.25 | 19.04±4.72 | 0.802 | 0.847 | 0.004 | -- |
| **IGF1 (ng/ml)**       | 125.88±63.47 | 134.28±68.65 | 140.74±60.91 | 0.195 | 0.098 | 0.073 | -- |
| HbA1c (%)              | 8.10±1.92 | 8.01±1.73 | 8.15±1.74 | 0.852 | 0.798 | -0.013 | -- |

T2DM – type 2 diabetes mellitus; IGF1 – insulin like growth factor 1; CA – cytosine-adenosine; BMI – body mass index; OGTT – oral glucose tolerance test; HDL-cholesterol – high-density lipoprotein cholesterol; LDL-cholesterol – low-density lipoprotein cholesterol; HbA1c – hemoglobin A1c; AUC – area under the curve; HOMA-S – homeostasis model assessment-sensitivity; HOMA-B – homeostasis model assessment-beta. * Log-transformed before multiple linear regression analysis.
Table 3. Clinical characteristics of the 389 study population according to SNP rs5742612 and multiple linear regression analysis for association of rs5742612 with metastatic traits.

|                      | TT   | CT   | CC   | P     | P (CT+CC vs. TT) | β     | SE  | R² (%) | P    |
|----------------------|------|------|------|-------|------------------|-------|-----|--------|------|
| N (M/F)              | 126/85 | 88/55 | 22/13 | 0.907 | 0.679            |       |     |        |      |
| Age (years)          | 65±9  | 64±10 | 66±11 | 0.429 | 0.397            |       |     |        |      |
| Family history of T2DM (Y/N) | 115/96 | 79/64 | 22/13 | 0.652 | 0.683            |       |     |        |      |

**Anthropometry**

|                      |       |       |       |       |                   |       |     |        |      |
|----------------------|-------|-------|-------|-------|-------------------|-------|-----|--------|------|
| Height (cm)          | 166.15±8.23 | 167.59±7.71 | 168.11±8.30 | 0.090 | 0.060            |       |     |        |      |
| BMI (kg/m²)          | 24.80±3.56 | 25.85±3.34 | 25.02±3.22 | 0.026 | 0.012            |       |     |        |      |
| Total cholesterol (mmol/l) | 3.38±1.17 | 2.95±1.02 | 3.04±0.95 | 0.002 | 0.001            |       |     |        |      |
| Triacylglycerol (mmol/l) | 1.42 (0.90, 1.96) | 1.24 (0.88, 1.80) | 1.34 (0.86, 1.97) | 0.246 | 0.099            |       |     |        |      |
| HDL-cholesterol (mmol/l) | 0.74 (0.61, 0.94) | 0.70 (0.53, 0.91) | 0.75 (0.61, 0.93) | 0.413 | 0.227            |       |     |        |      |
| LDL-cholesterol (mmol/l) | 2.02 (1.56, 2.57) | 1.76 (1.38, 2.28) | 1.97 (1.44, 2.27) | 0.006 | 0.002            |       |     |        |      |
| VLDL-cholesterol (mmol/l) | 0.65 (0.41, 0.88) | 0.59 (0.40, 0.82) | 0.57 (0.37, 0.88) | 0.188 | 0.076            |       |     |        |      |

**OGTT**

|                      |       |       |       |       |                   |       |     |        |      |
|----------------------|-------|-------|-------|-------|-------------------|-------|-----|--------|------|
| Fasting insulin (mU/L) | 10.99 (6.72, 19.74) | 12.20 (7.71, 28.72) | 14.23 (7.83, 21.83) | 0.070 | 0.022            |       |     |        |      |
| 60-min insulin (mU/L) | 29.67 (18.10, 48.02) | 37.52 (20.77, 72.25) | 38.74 (16.30, 47.73) | 0.037 | 0.010            |       |     |        |      |
| 120-min insulin (mU/L) | 35.13 (20.02, 59.49) | 42.09 (22.43, 73.47) | 42.00 (24.37, 76.26) | 0.090 | 0.029            |       |     |        |      |
| Fasting peptide C (ng/ml) | 2.47 (1.79, 3.64) | 2.86 (2.07, 4.24) | 2.67 (1.71, 3.50) | 0.031 | 0.024            |       |     |        |      |
| 60-min peptide C (ng/ml) | 4.52 (3.07, 6.24) | 4.97 (3.57, 7.90) | 4.83 (3.36, 6.46) | 0.070 | 0.028            |       |     |        |      |
| 120-min peptide C (ng/ml) | 5.69 (3.95, 8.23) | 6.61 (4.06, 9.69) | 7.05 (4.34, 8.57) | 0.221 | 0.082            |       |     |        |      |
| Fasting glucose (mmol/L) | 10.35±4.07 | 10.94±4.30 | 9.27±3.22 | 0.073 | 0.528            |       |     |        |      |
| 60-min glucose (mmol/L) | 16.66±3.97 | 16.91±4.16 | 17.20±4.40 | 0.633 | 0.386            |       |     |        |      |
| 120-min glucose (mmol/L) | 18.63±5.23 | 18.14±5.31 | 19.49±4.77 | 0.449 | 0.882            |       |     |        |      |

**Insulin sensitivity**

|                      |       |       |       |       |                   |       |     |        |      |
|----------------------|-------|-------|-------|-------|-------------------|-------|-----|--------|------|
| HOMA-S index*        | 0.23 (0.11, 0.38) | 0.17 (0.07, 0.32) | 0.19 (0.10, 0.34) | 0.037 | 0.018 | -0.131 | 0.049 | 5.8 | 0.008 |
| Fasting insulin (mU/L)** | 10.99 (6.72, 19.74) | 13.20 (7.71, 28.72) | 14.23 (7.83, 21.83) | 0.070 | 0.022 | 0.120 | 0.044 | 6.0 | 0.006 |

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Table 3 continued. Clinical characteristics of the 389 study population according to SNP rs5742612 and multiple linear regression analysis for association of rs5742612 with metastatic traits.

|                  | TT       | CT       | CC       | P       | β       | SE     | R² (%) | P    |
|------------------|----------|----------|----------|---------|---------|--------|--------|------|
| Insulin secretion|          |          |          |         |         |        |        |      |
| HOMA-B index (%)a | 41.99 (21.34, 85.51) | 47.54 (23.00, 102.88) | 52.85 (30.06, 100.11) | 0.198  | 0.092  | 0.099  | 0.048  | 3.8  | 0.008 |
| Insulin AUC (mU/L*h)a | 55.03 (31.50, 86.13) | 68.71 (40.04, 129.00) | 71.04 (35.26, 93.00) | 0.047  | 0.013  | 0.112  | 0.042  | 6.1  | 0.012 |
| Glucose tolerance|          |          |          |         |         |        |        |      |
| Glucose AUC (mmol/L*h) | 31.17±7.78 | 31.45±8.10 | 31.59±7.70 | 0.851  | 0.573  | 0.022  | –      | –    | 0.662 |
| Fasting glucose (mmol/L) | 10.35±4.07 | 10.94±4.30 | 9.27±3.22 | 0.073  | 0.528  | 0.029  | –      | –    | 0.564 |
| 120-min glucose (mmol/L) | 18.63±5.23 | 18.14±5.31 | 19.49±4.77 | 0.449  | 0.882  | 0.019  | –      | –    | 0.706 |
| IGF1 (ng/ml) | 132.12±69.10 | 128.82±61.49 | 143.44±60.44 | 0.448  | 0.914  | –0.015 | –      | –    | 0.748 |
| HbA1c (%) | 8.10±1.82 | 7.98±1.74 | 8.20±1.97 | 0.762  | 0.729  | –0.018 | –      | –    | 0.720 |

Table 4. Clinical characteristics of the 389 study population according to SNP rs2288377 and multiple linear regression analysis for association of rs2288377 with metastatic traits.

|                  | TT       | AT       | AA       | P       | β       | SE     | R² (%) | P    |
|------------------|----------|----------|----------|---------|---------|--------|--------|------|
| N (M/F)          | 124/81   | 87/52    | 25/20    | 0.701  | 1.000  |        |        |      |
| Age (years)      | 66±9     | 65±10    | 64±11    | 0.251  | 0.142  |        |        |      |
| Family history of T2DM (Y/N) | 112/93   | 75/64    | 29/16    | 0.437  | 0.759  |        |        |      |
| Anthropometry    |          |          |          |         |        |        |        |      |
| Height (cm)      | 166.25±8.28 | 167.56±7.73 | 167.47±8.07 | 0.131  | 0.116  |        |        |      |
| BMI (kg/m²)      | 24.75±3.59 | 25.84±3.34 | 25.29±3.11 | 0.021  | 0.007  |        |        |      |
| Total cholesterol (mmol/l) | 3.36±1.11 | 2.94±1.03 | 3.18±1.23 | 0.005  | 0.002  |        |        |      |
| Triacylglycerol (mmol/l) | 1.41 (0.90, 1.92) | 1.24 (0.86, 1.80) | 1.47 (0.93, 2.03) | 0.283  | 0.195  |        |        |      |
| HDL-cholesterol (mmol/l) | 0.74 (0.61, 0.95) | 0.69 (0.52, 0.91) | 0.73 (0.62, 0.91) | 0.416  | 0.215  |        |        |      |
| LDL-cholesterol (mmol/l) | 2.02 (1.56, 2.57) | 1.75 (1.35, 2.28) | 2.00 (1.52, 2.33) | 0.007  | 0.003  |        |        |      |
| VLDL-cholesterol (mmol/l) | 0.65 (0.41, 0.86) | 0.59 (0.40, 0.82) | 0.61 (0.41, 0.89) | 0.354  | 0.159  |        |        |      |

T2DM – type 2 diabetes mellitus; IGF1 – insulin like growth factor 1; CA – cytosine-adenosine; BMI – body mass index; OGTT – oral glucose tolerance test; HDL-cholesterol – high-density lipoprotein cholesterol; LDL-cholesterol – low-density lipoprotein cholesterol; HbA1c – hemoglobin A1c; AUC – area under the curve; HOMA-S – homeostasis model assessment-sensitivity; HOMA-B – homeostasis model assessment-beta. * Log-transformed before multiple linear regression analysis.
Table 4 continued. Clinical characteristics of the 389 study population according to SNP rs2288377 and multiple linear regression analysis for association of rs2288377 with metastatic traits.

|                           | TT       | AT       | AA       | P       | β        | SE     | R² (%) | P     |
|---------------------------|----------|----------|----------|---------|----------|--------|--------|-------|
| **OGTT**                  |          |          |          |         |          |        |        |       |
| Fasting insulin (mU/L)    | 10.87 (6.59, 19.14) | 13.20 (7.66, 29.69) | 15.97 (9.58, 25.98) | 0.009 | 0.003   |
| 60-min insulin (mU/L)     | 29.35 (17.90, 47.24) | 38.85 (21.02, 73.19) | 38.74 (19.51, 51.16) | 0.009 | 0.002   |
| 120-min insulin (mU/L)    | 34.86 (19.98, 59.21) | 42.09 (23.27, 74.23) | 42.43 (23.36, 68.43) | 0.035 | 0.010   |
| Fasting peptide C (ng/ml) | 2.43 (1.78, 3.59) | 2.94 (2.06, 4.24) | 2.68 (1.85, 3.60) | 0.011 | 0.003   |
| 60-min peptide C (ng/ml)  | 4.48 (2.99, 6.15) | 5.01 (3.62, 7.99) | 4.91 (3.33, 7.10) | 0.018 | 0.005   |
| 120-min peptide C (ng/ml) | 5.63 (3.90, 8.00) | 6.64 (4.11, 10.04) | 6.99 (4.17, 8.57) | 0.092 | 0.030   |
| Fasting glucose (mmol/L)  | 10.29±4.06 | 10.84±4.25 | 10.16±3.87 | 0.294 | 0.406   |
| 60-min glucose (mmol/L)   | 16.63±4.00 | 16.82±4.16 | 17.48±4.14 | 0.502 | 0.368   |
| 120-min glucose (mmol/L)  | 18.70±5.21 | 18.04±5.26 | 19.26±5.11 | 0.424 | 0.690   |
| **Insulin sensitivity**   |          |          |          |         |          |        |        |       |
| HOMA-S index*             | 0.23 (0.12, 0.39) | 0.17 (0.06, 0.32) | 0.16 (0.07, 0.26) | 0.006 | 0.002   | -0.159 | 0.049 | 6.6   | 0.001 |
| Fasting insulin(mU/L)*    | 10.87 (6.59, 19.14) | 13.20 (7.66, 29.69) | 15.97 (9.58, 25.98) | 0.009 | 0.003   | 0.143  | 0.043 | 6.8   | 0.001 |
| **Insulin secretion**     |          |          |          |         |          |        |        |       |
| HOMA-B index (%)*         | 39.89 (21.00, 84.92) | 48.94 (25.68, 105.11) | 52.85 (30.60, 94.80) | 0.095 | 0.037   | 0.114  | 0.048 | 4.2   | 0.017 |
| Insulin AUC (mU/L)*       | 53.58 (31.16, 86.07) | 69.06 (40.07, 133.36) | 72.10 (36.36, 94.17) | 0.011 | 0.003   | 0.042  | 0.030 | 6.7   | 0.002 |
| **Glucose tolerance**     |          |          |          |         |          |        |        |       |
| Glucose AUC (mmol/L)*     | 31.15±7.83 | 31.26±8.03 | 32.19±7.73 | 0.762 | 0.583   | 0.022  | –     | –     | 0.662 |
| Fasting glucose (mmol/L)  | 10.29±4.06 | 10.84±4.25 | 10.16±3.87 | 0.294 | 0.406   | 0.042  | –     | –     | 0.407 |
| 120-min glucose (mmol/L)  | 18.70±5.21 | 18.04±5.26 | 19.26±5.11 | 0.424 | 0.690   | -0.034 | –     | –     | 0.503 |
| IGF1 (ng/ml)              | 134.080±68.88 | 130.300±59.80 | 127.070±68.44 | 0.735 | 0.452   | -0.046 | –     | –     | 0.333 |
| HbA1c (%)                 | 8.12±1.84 | 7.92±1.64 | 8.27±2.11 | 0.497 | 0.553   | -0.031 | –     | –     | 0.543 |

T2DM – type 2 diabetes mellitus; IGF1 – insulin like growth factor 1; CA – cytosine-adenosine; BMI – body mass index; OGTT – oral glucose tolerance test; HDL-cholesterol – high-density lipoprotein cholesterol; LDL-cholesterol – low-density lipoprotein cholesterol; HbA1c – hemoglobin A1c; AUC – area under the curve; HOMA-S – homeostasis model assessment-sensitivity; HOMA-B – homeostasis model assessment-beta. * Log-transformed before multiple linear regression analysis.
### Table 5. Clinical characteristics of the 389 study population according to SNP haplotype and multiple linear regression analysis for association of SNP haplotype with metastatic traits.

|                        | CTT       | TCA       | TTT       | P (AT+AA vs. TT) | β       | SE     | R² (%) | P       |
|------------------------|-----------|-----------|-----------|------------------|---------|--------|--------|---------|
| N (M/F)                | 293/192   | 132/81    | 47/33     | 0.866            |         |        |        |         |
| Age (years)            | 65±9      | 65±10     | 67±9      | 0.163            |         |        |        |         |
| Family history of T2DM (Y/N) | 270/215   | 123/90    | 39/41     | 0.384            |         |        |        |         |

### Anthropometry

|                        | CTT       | TCA       | TTT       | P       | β       | SE     | R² (%) | P       |
|------------------------|-----------|-----------|-----------|---------|---------|--------|--------|---------|
| Height (cm)            | 166.7±7.97| 167.7±7.88| 165.3±8.87| 0.061   |         |        |        |         |
| BMI (kg/m²)            | 25.1±3.27 | 25.5±3.30 | 24.4±4.80 | 0.035   |         |        |        |         |
| Total cholesterol (mmol/l) | 3.2±1.16   | 2.9±1.00  | 3.2±1.07  | 0.007   |         |        |        |         |
| Triacylglycerol (mmol/l) | 1.40 (0.91, 0.58) | 1.29 (0.87, 1.82) | 1.28 (0.87, 1.80) | 0.257   |         |        |        |         |
| HDL-cholesterol (mmol/l) | 0.73 (0.58, 0.93) | 0.72 (0.58, 0.92) | 0.81 (0.62, 0.96) | 0.324   |         |        |        |         |
| LDL-cholesterol (mmol/l) | 1.96 (1.53, 2.51) | 1.81 (1.40, 2.27) | 1.95 (1.47, 2.49) | 0.021   |         |        |        |         |
| VLDL-cholesterol (mmol/l) | 0.64 (0.42, 0.85) | 0.57 (0.39, 0.82) | 0.58 (0.40, 0.82) | 0.122   |         |        |        |         |

### OGGT

|                        | CTT       | TCA       | TTT       | P       | β       | SE     | R² (%) | P       |
|------------------------|-----------|-----------|-----------|---------|---------|--------|--------|---------|
| Fasting insulin (mU/L) | 11.23 (6.87, 21.58) | 13.72 (7.79, 27.19) | 11.63 (7.56, 17.95) | 0.111   |         |        |        |         |
| 60-min insulin (mU/L)  | 31.66 (18.37, 55.66) | 38.74 (20.46, 67.73) | 28.61 (17.75, 43.33) | 0.019   |         |        |        |         |
| 120-min insulin (mU/L) | 35.46 (20.30, 65.78) | 42.00 (22.94, 73.85) | 35.07 (21.36, 66.40) | 0.101   |         |        |        |         |
| Fasting peptide C (ng/ml) | 2.62 (1.87, 3.83) | 2.79 (1.99, 3.92) | 2.37 (1.81, 2.34) | 0.123   |         |        |        |         |
| 60-min peptide C (ng/ml) | 4.63 (3.20, 6.81) | 4.91 (3.39, 7.53) | 4.36 (2.76, 6.24) | 0.059   |         |        |        |         |
| 120-min peptide C (ng/ml) | 5.92 (4.03, 8.53) | 6.73 (4.29, 9.48) | 5.37 (3.58, 8.67) | 0.178   |         |        |        |         |
| Fasting glucose (mmol/L) | 10.59±4.25 | 10.39±4.04 | 10.20±3.07 | 0.724   |         |        |        |         |
| 60-min glucose (mmol/L)  | 16.77±4.07 | 17.01±4.22 | 16.40±3.69 | 0.452   |         |        |        |         |
| 120-min glucose (mmol/L) | 18.46±5.32 | 18.58±5.15 | 18.77±4.77 | 0.900   |         |        |        |         |

### Insulin sensitivity

|                        | CTT       | TCA       | TTT       | P       | β       | SE     | R² (%) | P       |
|------------------------|-----------|-----------|-----------|---------|---------|--------|--------|---------|
| HOMA-S index*          | 0.21 (0.10, 0.37) | 0.18 (0.07, 0.32) | 0.21 (0.13, 0.31) | 0.157   | -0.033  |        | 0.355  |         |
| Fasting insulin (mU/L)** | 11.23 (6.87, 21.58) | 13.72 (7.79, 27.19) | 11.63 (7.56, 17.95) | 0.111   | 0.040   |        | 0.254  |         |

© Med Sci Monit, 2017; 23: 3722-3736

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Table 5 continued. Clinical characteristics of the 389 study population according to SNP haplotype and multiple linear regression analysis for association of SNP haplotype with metastatic traits.

| Clinical characteristic | CTT | TCA | TTT | P  | P (AT+ AA vs. TT) | β   | SE | R² (%) | P      |
|-------------------------|-----|-----|-----|----|------------------|-----|----|--------|--------|
| **Insulin secretion**   |     |     |     |    |                  |     |    |        |        |
| HOMA-B index (%)        | 43.15 | 48.94 | 36.63 | 0.159 | 0.034 | –  | – | 0.339 |
| Glucose tolerance       |     |     |     |    |                  |     |    |        |        |
| Glucose AUC (mg/dL)     | 31.30±8.03 | 31.49±7.93 | 30.89±6.69 | 0.747 | –0.007 | –  | – | 0.842 |
| Fasting glucose (mg/dL) | 10.59±4.25 | 10.39±4.04 | 10.20±3.07 | 0.724 | –0.027 | –  | – | 0.440 |
| 120-min glucose (mg/dL) | 18.46±5.32 | 18.58±5.15 | 18.77±4.77 | 0.900 | 0.016 | –  | – | 0.647 |
| IGF1 (ng/ml)            | 120.00 | 134.00 | 130.50 | 0.158 | 0.026 | 0.013 | 11.8 | 0.042 |
| HbA1c (%)               | 8.07±1.85 | 8.05±1.81 | 8.10±1.48 | 0.994 | –0.004 | –  | – | 0.907 |

T2DM – type 2 diabetes mellitus; IGF1 – insulin like growth factor 1; CA – cytosine-adenosine; BMI – body mass index; OGTT – oral glucose tolerance test; HDL-cholesterol – high-density lipoprotein cholesterol; LDL-cholesterol – low-density lipoprotein cholesterol; HbA1c – hemoglobin A1c; AUC – area under the curve; HOMA-S – homeostasis model assessment-sensitivity; HOMA-B – homeostasis model assessment-beta. * Log-transformed before multiple linear regression analysis.

Table 6. Clinical characteristics of the 389 study population according to SNP&CA haplotype and multiple linear regression analysis for association of SNP&CA haplotype with metastatic traits.

| Clinical characteristic | C19TT | C17TT | C18TT | T21CA | P  | β   | SE | R² (%) | P      |
|-------------------------|-------|-------|-------|-------|----|-----|----|--------|--------|
| N (M/F)                 | 133/81 | 47/28 | 82/58 | 87/62 | 0.915 |     |    |        |        |
| Age (years)             | 64±10 | 66±9  | 66±9  | 65±10 | 0.559 |     |    |        |        |
| Family history of T2DM  | 113/101 | 43/32 | 83/57 | 85/64 | 0.759 |     |    |        |        |
| Anthropometry           |       |       |       |       |      |     |    |        |        |
| Height (cm)             | 167.16±8.13 | 166.91±8.46 | 166.33±7.61 | 167.77±8.04 | 0.398 |     |    |        |        |
| BMI (kg/m²)             | 25.14±3.18 | 24.88±3.20 | 25.39±3.27 | 25.63±3.35 | 0.349 |     |    |        |        |
| Total cholesterol (mmol/l) | 3.33±1.21 | 3.31±1.12 | 3.23±1.08 | 2.99±0.98 | 0.045 |     |    |        |        |
| Triglycerol (mmol/l)    | (0.94, 1.91) | (0.84, 1.72) | (1.03, 2.03) | (0.91, 1.87) | 0.040 |     |    |        |        |
| HDL-cholesterol (mmol/l) | 0.74 (0.61, 0.95) | 0.74 (0.56, 0.91) | 0.73 (0.54, 0.92) | 0.58 (0.71, 0.92) | 0.580 |     |    |        |        |
| LDL-cholesterol (mmol/l) | 1.98 (1.59, 2.51) | 1.99 (1.47, 2.63) | 1.94 (1.55, 2.47) | 1.87 (1.40, 2.28) | 0.119 |     |    |        |        |
| VLDL-cholesterol (mmol/l) | 0.64 (0.43, 0.86) | 0.60 (0.40, 0.78) | 0.69 (0.48, 0.92) | 0.60 (0.42, 0.84) | 0.032 |     |    |        |        |
Table 6 continued. Clinical characteristics of the 389 study population according to SNP&CA haplotype and multiple linear regression analysis for association of SNP&CA haplotype with metastatic traits.

| Phenotype                        | C19TT                        | C17TT                        | C18TT                        | T21CA                        | P   | β     | SE  | R² (%) | P   |
|----------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-----|-------|-----|--------|-----|
| **OGTT**                         |                              |                              |                              |                              |     |       |     |        |     |
| Fasting insulin (mU/L)           | 12.21 (7.58, 24.37)          | 10.12 (6.65, 17.03)          | 10.71 (6.58, 21.64)          | 13.30 (7.79, 25.82)          | 0.127 |       |     |        |     |
| 60-min insulin (mU/L)            | 31.59 (18.28, 61.67)         | 33.34 (17.55, 53.73)         | 30.28 (18.34, 57.96)         | 38.85 (20.03, 60.19)         | 0.475 |       |     |        |     |
| 120-min insulin (mU/L)           | 36.25 (20.08, 66.42)         | 34.86 (19.16, 58.55)         | 36.90 (21.68, 69.72)         | 42.00 (22.09, 69.6)          | 0.531 |       |     |        |     |
| Fasting peptide C (ng/ml)        | 2.67 (1.93, 3.91)            | 2.47 (1.41, 3.59)            | 2.63 (1.94, 3.80)            | 2.82 (1.99, 3.78)            | 0.326 |       |     |        |     |
| 60-min peptide C (ng/ml)         | 4.53 (3.27, 7.24)            | 4.72 (2.99, 6.32)            | 4.46 (3.03, 6.82)            | 4.91 (3.40, 7.12)            | 0.747 |       |     |        |     |
| 120-min peptide C (ng/ml)        | 5.91 (4.08, 8.60)            | 5.69 (3.78, 8.49)            | 5.86 (4.02, 8.42)            | 6.64 (3.96, 9.00)            | 0.808 |       |     |        |     |
| Fasting glucose (mmol/L)         | 10.64±4.31                   | 10.23±4.42                   | 10.79±4.20                   | 10.47±4.19                   | 0.751 |       |     |        |     |
| 60-min glucose (mmol/L)          | 16.72±4.00                   | 17.12±3.95                   | 16.78±4.31                   | 16.84±4.06                   | 0.951 |       |     |        |     |
| 120-min glucose (mmol/L)         | 18.48±5.24                   | 19.00±5.10                   | 18.35±5.74                   | 18.35±5.07                   | 0.919 |       |     |        |     |
| **Insulin sensitivity**          |                              |                              |                              |                              |     |       |     |        |     |
| HOMA-S index*                    | 0.20 (0.09, 0.34)            | 0.26 (0.12, 0.43)            | 0.20 (0.09, 0.37)            | 0.19 (0.07, 0.33)            | 0.132 | -0.014 | - | - | 0.696 |
| Fasting insulin (mU/L)*          | 12.21 (7.58, 24.37)          | 10.12 (6.65, 17.03)          | 10.71 (6.58, 21.64)          | 13.30 (7.79, 25.82)          | 0.127 | 0.019 | - | - | 0.588 |
| **Insulin secretion**            |                              |                              |                              |                              |     |       |     |        |     |
| HOMA-B index (%)*                | 42.04 (22.45, 99.63)         | 44.01 (20.21, 89.23)         | 42.70 (21.38, 91.99)         | 52.85 (25.37, 101.49)        | 0.554 | 0.016 | - | - | 0.651 |
| Insulin AUC (mU/L*h)*            | 61.39 (33.58, 95.35)         | 61.59 (30.47, 77.72)         | 56.14 (31.41, 120.03)        | 69.93 (37.52, 117.41)        | 0.501 | 0.022 | - | - | 0.528 |
| **Glucose tolerance**            |                              |                              |                              |                              |     |       |     |        |     |
| Glucose AUC (mmol/L*h)           | 31.28±7.94                   | 31.74±7.93                   | 31.35±8.47                   | 31.25±7.87                   | 0.989 | -0.009 | - | - | 0.797 |
| Fasting glucose (mmol/L)         | 10.64±4.31                   | 10.23±4.42                   | 10.79±4.20                   | 10.47±4.19                   | 0.751 | -0.027 | - | - | 0.440 |
| 120-min glucose (mmol/L)         | 18.48±5.24                   | 19.00±5.10                   | 18.35±5.74                   | 18.35±5.07                   | 0.919 | 0.001 | - | - | 0.988 |
| IGF1 (ng/ml)                     | 119.50 (80.90, 173.25)       | 134.00 (77.90, 155.00)       | 129.00 (82.88, 189.25)       | 137.00 (93.60, 175.50)       | 0.742 | 0.044 | - | - | 0.190 |
| HbA1c (%)                        | 7.99±1.74                    | 8.46±2.02                    | 8.04±1.86                    | 8.06±1.80                    | 0.368 | -0.009 | - | - | 0.791 |

T2DM – type 2 diabetes mellitus; IGF1 – insulin like growth factor 1; CA – cytosine-adenosine; BMI – body mass index; OGTT – oral glucose tolerance test; HDL-cholesterol – high-density lipoprotein cholesterol; LDL-cholesterol – low-density lipoprotein cholesterol; HbA1c – hemoglobin A1c; AUC – area under the curve; HOMA-S – homeostasis model assessment-sensitivity; HOMA-B – homeostasis model assessment-beta. * Log-transformed before multiple linear regression analysis.
rs35767

No significant rs35767 genotype-related differences in gender, age, family history of T2DM, or anthropometric or metabolic parameters were observed, nor in IGF1 level. However, the CC homozygote subjects exhibited higher levels of total cholesterol and LDL cholesterol than the CT/TT carriers. The linear regression analysis showed no significant correlation of metabolic parameters with rs35767 polymorphism (Table 2).

rs5742612

Subjects with the rs5742612 genotypes showed significantly different BMI, total cholesterol, and LDL cholesterol, but no significant differences in gender, age, or family history of T2DM. Additionally, a significant difference between the TT and CT/CC genotypes was observed in fasting insulin (10.99 [6.72, 19.74] vs. 13.30 [7.73, 27.74] mU/L, P=0.022); 60-min insulin (29.67 [18.10, 48.02] vs. 38.13 [20.61, 70.42] mU/L, P=0.010); 120-min insulin (35.13 [20.02, 59.49] vs. 42.05 [22.57, 73.66] mU/L, P=0.029); fasting peptide C (2.47 [1.79, 3.64] vs. 2.81 [2.02, 3.93] ng/mL, P=0.024); 60-min peptide C (4.52 [3.07, 6.24] vs. 4.93 [3.41, 7.76] ng/mL, P=0.028) during OGTT; and HOMA-S index (0.23 [0.11, 0.38] vs. 0.17 [0.07, 0.32], P=0.018); and insulin AUC (55.03 [31.50, 86.13] vs. 69.49 [37.85, 120.57] mU/L*h, P=0.013). However, a difference between the genotypes with regard to the glucose levels during the OGTT, glucose AUC, or IGF1 level was not observed. In the meantime, the C allele of rs5742612 was found to be associated with decreased insulin sensitivity (HOMA-S index, β=−0.131, P=0.008; fasting insulin level, β=0.022, P=0.006) and increased insulin secretion (HOMA-B index, β=0.099, P=0.008; insulin AUC, β=0.112, P=0.012), after controlling for the effects of gender, age, and BMI according to the multiple linear regression model (Table 3).

rs2288377

Subjects with the rs2288377 genotype showed significantly different BMI, total cholesterol, and LDL cholesterol, but no significant differences in gender, age, or family history of T2DM. Moreover, we confirmed significant differences in fasting insulin (10.87 [6.59, 19.14] vs. 13.98 [7.84, 28.48] mU/L, P=0.003); 60-min insulin (29.35 [17.90, 47.24] vs. 38.80 [21.14, 71.23] mU/L, P=0.002); 120-min insulin (34.86 [19.98, 59.21] vs. 42.26 [23.40, 74.04] mU/L, P=0.010); fasting peptide C (2.43 [1.78, 3.59] vs. 2.88 [2.03, 4.16] ng/mL, P=0.003); 60-min peptide C (4.48 [2.99, 6.15] vs. 4.96 [3.44, 7.89] ng/mL, P=0.005); and 120-min peptide C (5.63 [3.90, 8.00] vs. 6.74 [4.15, 9.67] ng/mL, P=0.030) during OGTT and HOMA-S index (0.23 [0.12, 0.39] vs. 0.17 [0.06, 0.31], P=0.032); HOMA-B index (39.89 [21.00, 84.92] vs. 49.84 [25.89, 102.48], P=0.037); and insulin AUC (53.58 [31.16, 86.07] vs. 71.24 [39.12, 120.57] mU/L*h, P=0.003) among carriers of the TT, AT/AA genotype. Nevertheless, no significant difference between the genotypes with regard to the glucose levels during the OGTT, glucose AUC, and IGF1 level was observed. The linear regression model indicated that the A allele of rs2288377 was associated with decreased insulin sensitivity (HOMA-S index, β=−0.159, P=0.001; fasting insulin, β=0.143, P=0.001) and increased insulin secretion (HOMA-B index, β=0.114, P=0.017; insulin AUC, β=0.042, P=0.002), independent of gender, age, and BMI (Table 4).

SNP haplotype

Subjects with the SNP haplotype showed significantly different BMI, total cholesterol, and LDL cholesterol, but no significant differences in gender, age, or family history of T2DM. We also observed a significant difference between the CTT, TCA, and TTT haplotypes in 60-min insulin (31.66 [18.37, 55.66] vs. 38.74 [20.46, 67.73] vs. 28.61 [17.75, 43.33], P=0.019); insulin AUC (60.79 [32.92, 95.18] vs. 69.93 [37.52, 120.18] vs. 51.55 [34.00, 92.10], P=0.040); and IGF1 (128.98±65.42 vs. 133.62±61.25 vs. 145.23±75.80, P=0.049). The linear regression analysis showed no significant correlation between metabolic parameters and rs35767 polymorphism, except IGF1 (β=7.631, P=0.020), independent of gender, age, and BMI (Table 5).

SNP&CA haplotype

Four common haplotypes were compared in our study. We observed a significant difference in BMI, total cholesterol, and LDL cholesterol among subjects with different SNP&CA haplotypes. However, there were no significant SNP&CA haplotype-related differences in gender, age, family history of T2DM, or metabolic parameters, nor in IGF1 level. The linear regression analysis also showed no significant correlation between metabolic parameters and the SNP&CA haplotype (Table 6).

Discussion

Diabetes turns up when elevation in insulin secretion is insufficient to overcome tissue insulin resistance. Insulin resistance is thought to result mainly from environmental factors, such as obesity. However, there is compelling evidence that both insulin sensitivity and insulin secretion also have a genetic component [19]. IGF1 is a growth factor of significant homology with insulin and has been widely reported to elevate insulin sensitivity [20–22]. The gene coding IGF1 is the IGF1 gene (NG 011713.1GI: 225735562), the CA microsatellite and SNPs with insulin sensitivity and secretion =−0.159, P=0.001; fasting insulin, P=0.001) and increased insulin secretion (HOMA-B
statistical contribution to insulin sensitivity or insulin secretion of different CA microsatellite or rs35767 polymorphisms, nor of the SNP haplotype only or the SNP with CA microsatellite haplotype. We also confirmed that the rs5742612 and rs2288377 polymorphisms were associated with insulin sensitivity and insulin secretion, with carriers of the TT genotype exhibiting higher insulin sensitivity and lower insulin secretion, respectively, independent of gender, age, and BMI. However, correlation of the studied microsatellite, SNPs, and haplotypes with circulating IGF1 concentration was observed only in the SNP haplotype without the CA microsatellite.

Studies for correlation of the CA microsatellite with risk of type 2 diabetes and insulin sensitivity have led to controversial conclusions. Prior studies examining the role of the CA microsatellite in IGF1 regarding predisposition to common human disease have found the variant inconsistently, with the same allele associated with high [12] and low [23] risk of T2DM, respectively. Different from the CA microsatellite research, on the SNPs came to a consistent conclusion. A recent meta-analysis of a genome-wide association study of β cell function and insulin resistance in an East Asian population showed weak association between the rs35767 polymorphisms and insulin resistance with 0.009 HOMA-IR rise per G allele [24], while a previous meta-analysis revealed a 0.010 pmol/L per G allele increase in fasting insulin level [3]. Similarly, Mannino et al. proposed that the rs35767 was associated with circulating insulin sensitivity and IGF1 levels, with carriers of the GG genotype exhibiting lower insulin sensitivity and IGF1 concentrations compared with subjects carrying the A allele [14]. However, the correlation of the CA microsatellite and rs35767 polymorphisms with insulin sensitivity and secretion was not observed in our research. The inconsistent and opposite findings of association between IGF1 gene variation and insulin sensitivity may be due to a number of factors [23]. Differences in environmental factors may contribute to the inconsistent findings, in particular in relation to the selection of study subjects and their demographic, clinical, and metabolic characteristics [25].

In addition, we observed a significant association of metabolic parameters with the rs5742612 and rs2288377 polymorphisms for the first time. Carriers of the TT genotype exhibited higher insulin sensitivity and lower insulin secretion and insulin and peptide C levels during OGTT compared with subjects carrying the C allele and A allele, respectively. In the linear regression analysis, the rs5742612 donated 0.131 HOMA-S reductions and 0.099 HOMA-B rises per C allele, and the rs2288377 polymorphism donated 0.159 HOMA-S reductions and 0.143 HOMA-B rises per A allele, respectively, independently of age, gender, and BMI. However, no significant association was found between the rs5742612 or rs2288377 polymorphisms and serum IGF1 levels, glucose tolerance, or Hba1c levels. We presumed that the associations of the rs5742612 and rs2288377 SNPs with insulin sensitivity and insulin secretion might be attributed to the direct functional roles of the two loci or be mediated by circulating IGF1. The first hypothesis is that these SNPs might tag other variants in the IGF1 gene associated with insulin sensitivity and β cell function. In a recent study, the investigators revealed plenty of rare variants associated with fasting insulin levels that had not been previously described, by further study of the IGF1 gene [26]. Examination showed that the variants were located near the DNasel hypersensitive sites and FOXA1 binding sites, indicating that they might have direct function because FOXA1 is a major transcriptional regulator factor in glucose homeostasis and insulin metabolism [27,28]. The rs5742612 and rs2288377 SNPs might tag these variants and have direct function in insulin secretion and glucose homeostasis. Alternatively, the associations may be mediated by circulating IGF1. Low circulating IGF1 levels may result in GH over-secretion by negative feedback on the pituitary and/or hypothalamus [29]. Thereby, inactivation of GH in liver IGF1-deficient mice resulted in decreased blood glucose and increased insulin sensitivity [29]. These results suggest that enhanced GH secretion may be a major mediator of low insulin sensitivity in subjects with low circulating IGF1 levels. To solve this confusion, we investigated the association of SNP-only and SNP with CA haplotypes with insulin sensitivity and secretion for the first time, but no significant difference was observed. However, we did observe that the SNP-only haplotype was associated with circulating IGF1 levels. This potentially can exclude the possibility that the functional role of IGF1 SNP loci was mediated by circulating IGF1, nor was it mediated by interaction with the CA microsatellite. It is likely that the difference was attributable to the direct functional roles of the two loci. However, the precise molecular mechanism of the effect on insulin sensitivity and secretion by these gene polymorphisms requires further investigations.

There were some limitations in our study. Due to the limitations of the cross-sectional study itself, we couldn’t come to a causative conclusion. Studies in human cell culture and animal models will be needed to validate the function of these noncoding variants in insulin biology. Moreover, the β values were small, which indicated our study could only explain a small portion of the insulin biology variation. Finally, our results were based on the Han Chinese; further studies are needed to validate the conclusion in other races.

Conclusions

In conclusion, our study has identified the association of the CA microsatellite and rs35767 polymorphisms and for the first time, the rs5742612 and rs2288377 polymorphisms and SNP haplotypes in the ECR of the IGF1 promoter with insulin sensitivity and secretion. There was no CA microsatellite or
rs35767 genotype-related insulin sensitivity or secretion. The rs5742612 and rs2288377 polymorphisms were significantly associated with insulin sensitivity and insulin secretion, with the TT genotype exhibiting higher insulin sensitivity and lower insulin secretion compared with carriers of the C allele and A allele, respectively. We consider that the correlation is attributable to the direct functional roles of the two loci. Our results have important significance in understanding the correlation of the CA microsatellite and SNPs in the ECR of the IGF1 promoter with insulin biology. Further study incorporating a more systematic approach to identify the molecular mechanisms for the association is needed.

References:

1. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care, 2009; 32(Suppl. 1): S62–67
2. Morris AP, Voight BF, Teslovich TM et al: Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet, 2012; 44(9): 981–90
3. Dupuis I, Langenberg C, Prokopenko I et al: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet, 2010; 42(2): 103–16
4. Billsung UK, Florez JC: The genetics of type 2 diabetes: What have we learned from GWAS? Ann NY Acad Sci, 2010; 1212: 59–77
5. Scott RA, Fall T, Pasko D et al: Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. Diabetes, 2014; 63(12): 4378–87
6. Seppa S, Voutilainen R, Tenhola S: Markers of insulin sensitivity in 12-year-old children born from preconceptional pregnancies. J Pediatr, 2015; 167(1): 125–30
7. Woods KA, Camacho-Hübner C, Bergman RN et al: Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab, 2000; 85(4): 1407–11
8. Succurro E, Andreozzi F, Marini MA et al: Low plasma insulin-like growth factor-I levels are associated with reduced insulin sensitivity and increased insulin secretion in nondiabetic subjects. Nutr Metab Cardiovasc Dis, 2009; 19(10): 713–19
9. Barner C, Petersson M, Edén Engström B, Höybye C: Effects on insulin sensitivity and body composition of combination therapy with GH and IGF1 in GH deficient adults with type 2 diabetes. Eur J Endocrinol, 2012; 167(5): 697–703
10. de Kerdanet M, Caron-Debarle M, Nivot S et al: Ten-year improvement of fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet, 2010; 42(2): 105–16
11. Mannino GC, Greco A, De Lorenzo C et al: A fasting insulin-raising allele at IGF1 locus is associated with circulating levels of IGF-1 and insulin sensitivity. PLoS One, 2013; 8(12): e85483
12. Serre D, Gund S, Ge B et al: Differential allelic expression in the human genome: A robust approach to identify genetic and epigenetic cis-acting mechanisms regulating gene expression. PLoS Genet, 2008; 4(2): e1000006
13. Chen HY, Chan IH, Sham AL et al: Haplotype effect in the IGF1 promoter accounts for the association between microsatellite and serum IGF1 concentration. Clin Endocrinol (Oxf), 2011; 74(4): 520–27
14. Chäfö SA, Machicao F, Fritsche A et al: New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Res Clin Pract, 2011; 93(Suppl. 1): 59–24
15. Yang S, Liu JL, Fernandez AM et al: Liver-specific igf1 gene deletion leads to muscle insulin insensitivity. Diabetes, 2001; 50(5): 1110–18
16. Moses AC, Young SC, Morrow LA et al: Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes, 1996; 45(1): 91–100
17. Hussain MA, Schmitz O, Mengel A et al: Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest, 1993; 92(5): 2249–56
18. Frayling TM, Hattersley AT, Smith GD, Ben-Shlomo Y: Conflicting results on variation in the IGF1 gene highlight methodological considerations in the design of genetic association studies. Diabetologia, 2002; 45(11): 1605–6
19. Hong K-W, Chung M, Cho SB: Meta-analysis of genome-wide association study of homeostasis model assessment β-cell function and insulin resistance in an East Asian population and the European results. Mol Genet Genomics, 2014; 289(6): 1247–55
20. Dunger DB, Ong KKL, Sandhu MS: Serum insulin-like growth factor-I levels and potential risk of type 2 diabetes. Horm Res, 2003; 60(Suppl. 3): 131–35
21. Willems SM, Cornes BK, Brody JA et al: Association of the IGF1 gene with fasting insulin levels. Eur J Hum Genet, 2016; 24(9): 1337–43
22. Gao N, Le Lay J et al: FoaX1 and FoaX2 maintain the metabolic and secretory features of the mature beta-cell. Mol Endocrinol, 2010; 24(8): 1594–604
23. Kaestner KH: The Foxa factors in organogenesis and differentiation. Curr Opin Genet Dev, 2010; 20(5): 527–32
24. Yang S, Setser J, Zhao H et al: Inhibition of growth hormone action improves insulin sensitivity in liver IGF1–deficient mice. J Clin Invest, 2004; 113(1): 96–105

Conflict of interests

The authors have no conflict of interests, and they didn’t receive any financial support for this study.

Acknowledgment

We would like to sincerely thank patients for providing blood samples.